Immutep Limited (NASDAQ:IMMP) Short Interest Update

Immutep Limited (NASDAQ:IMMP) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 1,260,000 shares, a growth of 10.5% from the March 15th total of 1,140,000 shares. Based on an average daily volume of 141,400 shares, the days-to-cover ratio is currently 8.9 days.

Immutep Stock Performance

Shares of IMMP opened at $2.31 on Tuesday. Immutep has a one year low of $1.50 and a one year high of $3.90. The stock has a 50-day moving average of $2.44 and a 200-day moving average of $2.21.

Institutional Investors Weigh In On Immutep

A number of hedge funds have recently added to or reduced their stakes in IMMP. Virtu Financial LLC bought a new position in shares of Immutep in the 4th quarter worth $29,000. Jane Street Group LLC acquired a new position in Immutep during the fourth quarter worth $38,000. Balyasny Asset Management LLC bought a new position in shares of Immutep in the third quarter valued at $55,000. GTS Securities LLC acquired a new position in shares of Immutep during the fourth quarter valued at about $59,000. Finally, BNP Paribas Financial Markets increased its position in shares of Immutep by 27.8% during the fourth quarter. BNP Paribas Financial Markets now owns 30,600 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 6,665 shares in the last quarter. Institutional investors and hedge funds own 2.32% of the company’s stock.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.